Recent Pfizer Press Releases

  • 7/30/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect againstmore...
  • 7/29/14 7:00 am EDT
    • Second-Quarter 2014 Reported Revenues(1) of $12.8 Billion
    • Second-Quarter 2014 Adjusted Diluted EPS(2) of $0.58, Reported Diluted EPS(1) of $0.45
    • Repurchased $2.9 Billion of Common Stock to Date in 2014
    • Reaffirmed 2014 Adjusted Diluted EPS(2) Guidance; Updated Certain Other 2014 Financial Guidance Components
    • Expects to Complete U.S. Regulatory Submission for Palbociclib in Advanced Breast Cancer in August 2014
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for second-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP)(3); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3); and the Global Established Pharmaceutical segment (GEP)(3).more...
  • 7/16/14 10:00 am EDT

    Pfizer’s Get Old Campaign Challenges Conventional Attitudes about Aging

    New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 20132

    NEW YORK--(BUSINESS WIRE)--Life expectancy continues to climb — up to more than 81 years for women and 76 years for men3 – but many of us have concerns around aging. Pfizer is challenging Americans to address their #FOGO – Fear of Getting Old – as the next phase of Get Old, an initiative by Pfizer around aging, encouraging honest conversations and celebrating getting “old” at whatever stage of life you are. “We want people to Get Old with a new attitude. If youmore...
  • 7/16/14 9:26 am EDT

    InnoPharma Has Established Track Record in the Development of Hard-to-Make, Differentiated, Sterile Injectable Products


    Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration

    NEW YORK and PISCATAWAY, N.J.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments. InnoPharma’s current portfolio includes 10 generic productsmore...
  • 7/16/14 7:00 am EDT

    Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX (100 IU/Kg) showed a statistically significantmore...
  • 6/26/14 11:20 am EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 26-cent third-quarter 2014 dividend on the company’s common stock, payable September 3, 2014, to shareholders of record at the close of business on August 1, 2014. The third-quarter 2014 cash dividend will be the 303rd consecutive quarterly dividend paid by Pfizer. About Pfizer Inc. At Pfizer, we apply science and our global resources to bring therapies to peoplemore...
  • 6/26/14 9:45 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the election of James C. Smith to its Board of Directors, effective immediately. Mr. Smith also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board. Mr. Smith, 54, is the President and Chief Executive Officer (CEO) of Thomson Reuters and serves on its Board of Directors. Prior to his appointment as CEO in January 2012, he held various leadership positionsmore...
  • 6/24/14 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2014 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.more...
  • 6/18/14 5:01 pm EDT

    Phase 3 Study ORAL Start Showed XELJANZ Monotherapy Superior to Methotrexate in Inhibiting the Progression of Structural Damage and Reducing Signs and Symptoms of Rheumatoid Arthritis in Methotrexate-Naïve Patients

    Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile of XELJANZ as Monotherapy in Rheumatoid Arthritis

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine. ORAL Start is a 24-month Phase 3 study in patients with moderately to severely active rheumatoid arthritis who had not previously received methotrexate. The study showed that XELJANZ (tofacitinib citrate) 5 mg and 10 mg twice daily, as monotherapy (e.g., taken without methotrexate),more...
  • 6/18/14 1:00 am EDT

    Collaboration to Utilize Cellectis’ Proprietary Allogeneic CAR-T Platform Technology to Develop Immunotherapies Against Select Targets in the Field of Oncology

    NEW YORK & PARIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine. ORAL Start is a 24-month Phase 3 study in patients with moderately to severely active rheumatoid arthritis who had not previously received methotrexate. The study showed that XELJANZ (tofacitinib citrate) 5 mg and 10 mg twice daily, as monotherapy (e.g., taken without methotrexate),more...